J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

It is shock, awe, dismay, hurt Fresh flowers now stand off the side of IL-23. The overnight collision happened near what neighbors call a dangerous intersection. "The noise it makes is just ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...